Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Sodium-Bicarbonate

Preparation Calculator

USE IF: Severe metabolic acidosis (selected causes), hyperkalemia adjunct, sodium-channel blocker toxicity (e.g., TCA), and selected urine alkalinization protocols.

AVOID IF: Routine mild acidosis without indication, uncontrolled volume overload, severe hypernatremia, alkalemia, or inappropriate empiric use without cause review.

Sodium Bicarbonate

Alkalinizing agent / emergency adjunct

AdultPediatricERICUToxicologyHigh-yield

Indication

Severe metabolic acidosis • Hyperkalemia adjunct • TCA/sodium-channel blocker toxicity • Selected alkalinization protocols

At a glance

INDICATIONS (CORE USE)

- Severe metabolic acidosis (selected, cause-specific) - Hyperkalemia (adjunct only) - TCA/sodium-channel blocker toxicity - Urine/serum alkalinization in selected toxicology pathways

ADULT DOSE (STANDARD)

Emergency/protocol-based dosing Bolus dosing for toxicity or severe acidosis as indicated Infusion may be used in selected ICU/toxicology pathways

MAX DOSE

No simple fixed maximum; guided by pH, sodium, potassium, ECG, and protocol context

Route

IV

PEDIATRIC DOSE

Specialist/protocol-based only

Do not miss

Must-not-miss safety points

Major warning

- NOT a universal treatment for acidosis - Hyperkalemia use is adjunctive and does NOT replace definitive stabilization/elimination strategy - Sodium load and volume load can worsen CHF or pulmonary edema - Overcorrection can cause alkalosis, hypokalemia, and reduced ionized calcium - TCA/sodium-channel blocker toxicity is a high-yield indication; treat ECG/QRS targets, not just numbers

Indications

Primary

  • Severe metabolic acidosis with clear indication
  • TCA/sodium-channel blocker toxicity
  • Hyperkalemia (adjunct)

Secondary

  • Selected toxicology alkalinization protocols

Dosing

STANDARD (ADULT PO)

Protocol-based IV bolus and/or infusion depending on indication.

ADULT DOSE

Dose strategy is indication-specific and target-guided (acid-base, ECG/QRS, potassium, sodium, and hemodynamic context). Use ICU/toxicology protocol targets rather than fixed empiric schedules.

PEDIATRIC DOSE

Protocol-based only.

MAX DOSE

No universal fixed max; stop/escalate based on pH, bicarbonate, sodium, potassium, ECG, and clinical response.

Practical Note

- Severe acidosis: use selectively and treat underlying cause - Hyperkalemia: adjunct only, especially when significant acidosis coexists - TCA/sodium-channel blocker toxicity: bolus and/or infusion guided by ECG/QRS and pH targets per toxicology/ICU protocol - Frequent reassessment required

Warnings

Clinical warnings

  • Volume overload and hypernatremia risk
  • Metabolic alkalosis
  • Hypokalemia after correction
  • Reduced ionized calcium may worsen instability or tetany
  • Extravasation/line issues depending on concentration and route policy
  • Adverse effects: - Alkalosis - Hypernatremia - Hypokalemia - Fluid overload

Contraindications

  • Metabolic or respiratory alkalosis
  • Severe hypernatremia
  • Use extreme caution in CHF or severe volume overload
  • Known incompatibility/line issues per institutional protocol

Drug interactions

  • Other sodium-containing therapies may add sodium and volume burden
  • Calcium and potassium shifts may alter concurrent resuscitation decisions
  • Follow institutional compatibility policy for IV mixing and line use

Special populations

Pediatrics

Specialist/protocol-based only

Pregnancy

Use only when clinically indicated with protocol-based targets and multidisciplinary review where appropriate.

Lactation

See lactation references and product labeling.

Renal impairment

Acid-base and potassium indications may coexist, but sodium and volume tolerance remains critical to safe use.

Hepatic impairment

Hepatic function is not the primary dosing limiter; monitor whole physiologic context closely.

Elderly

Higher risk of volume overload and electrolyte shifts; monitor sodium, pH, potassium, and fluid balance closely.

Administration

- IV only - Bolus or infusion per protocol and indication - Follow line and compatibility guidance - Reassess pH, electrolytes, ECG, and volume status frequently

Monitoring

  • Monitor: - pH and bicarbonate - Sodium and potassium - Volume status - ECG when used for hyperkalemia or sodium-channel blocker toxicity
  • Recheck: - Frequently after bolus or during infusion - Repeat labs/ECG per protocol and clinical response
  • Hold if:
    - Alkalemia or overcorrection
    - Worsening volume overload
    - Significant hypernatremia
    - Clinical deterioration not responding as expected

Overdose / toxicity

Clinical Picture

Metabolic alkalosis, hypernatremia, hypokalemia, and volume overload.

Immediate Actions

Stop bicarbonate, provide supportive care, correct electrolytes/reassess acid-base status, and treat volume overload when present.

Antidote

None specific.

Decontamination

Not applicable for IV therapeutic overdose contexts.

Escalation

Escalate to ICU-level monitoring and targeted corrective therapy when severe derangements are present.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Best emergency use cases: TCA/sodium-channel blocker toxicity, severe acidosis with clear indication, and hyperkalemia with acidosis
  • Do not use reflexively for every low bicarbonate value

Clinical

  • Treat the cause, not just the number
  • In sodium-channel blocker toxicity, follow ECG/QRS and toxicology targets

Safety

  • Most common serious error is giving bicarbonate without reassessing sodium, pH, potassium, and volume status

Pharmacy Tool

Preparation Calculator

Sodium bicarbonate 1 mEq/mL oral solution

solution · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Immediate systemic buffering effect - Distribution and effect depend on ventilation and acid-base physiology

Mechanism of action

- Buffers hydrogen ions and increases serum bicarbonate - Also provides sodium load relevant in sodium-channel blockade

Common brand names

Saudi Arabia

Sodium bicarbonate (IV)

Global

Sodium bicarbonate, Sodium Bicarbonate Injection (generic)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Institutional ICU, emergency, and toxicology bicarbonate protocols
  • Hyperkalemia pathways emphasizing adjunctive role of bicarbonate
  • Toxicology guidance for sodium-channel blocker toxicity and ECG/QRS targets